Stockscreener 앱 받기
4.39
0.69%
0.03
전일 마감가:
$4.36
열려 있는:
$4.22
하루 거래량:
33,104
Relative Volume:
0.30
시가총액:
$38.79M
수익:
$140.46M
순이익/손실:
$-146.34M
주가수익비율:
-3.4567
EPS:
-1.27
순현금흐름:
$-117.73M
1주 성능:
-2.23%
1개월 성능:
-10.77%
6개월 성능:
-58.19%
1년 성능:
-71.31%
1일 변동 폭
$4.22
$4.53
1주일 범위
$4.19
$4.62
52주 변동 폭
$3.51
$17.40
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
4.39 | 38.79M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Two Sigma Investments LP - Defense World
Class Action ReminderNFLX, KPTI & MNKBronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Two Sigma Advisers LP Buys 45,400 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Millennium Management LLC Lowers Stock Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment By Investing.com - Investing.com Nigeria
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment - Investing.com
Karyopharm to Present at the Jefferies Global Healthcare Conference - Kilgore News Herald
Karyopharm to Present at the Jefferies Global Healthcare Conference | KPTI Stock News - GuruFocus
Northern Trust Corp Acquires 54,061 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI Stock News - GuruFocus
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Jane Street Group LLC - Defense World
Karyopharm increases share reserve for equity plan - Investing.com India
Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment - TipRanks
Karyopharm increases share reserve for equity plan By Investing.com - Investing.com UK
D. E. Shaw & Co. Inc. Sells 817,711 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Hepatic Impairment Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Novartis, ApoPharma, Indivior Inc., Boehringer Ingelheim, Ocera Therapeutics, Orient Europharma, Karyopharm - Barchart.com
Focus Partners Wealth Makes New Investment in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com India
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27% - simplywall.st
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet - simplywall.st
Karyopharm at RBC Capital Markets: Strategic Insights on XPOVIO and Pipeline - Investing.com Australia
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - Eastern Progress
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? - sharewise
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference | KPTI Stock News - GuruFocus
StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World
Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World
Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World
Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World
Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus
KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus
Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire
KPTI: RBC Capital Lowers Price Target while Maintaining Outperform Rating | KPTI Stock News - GuruFocus
RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada
KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
KPTI Misses Q1 Revenue Estimates but Advances Myelofibrosis Tria - GuruFocus
KPTI Stock Boosted as Barclays Raises Price Target to $10 | KPTI - GuruFocus
Karyopharm (KPTI) Target Price Reduced by RBC Capital | KPTI Sto - GuruFocus
KPTI: Baird Lowers Price Target but Maintains Outperform Rating - GuruFocus
Karyopharm (KPTI) Price Target Reduced by Baird, Outperform Rati - GuruFocus
Karyopharm Therapeutics Inc Reports Q1 2025 Earnings: EPS Loss o - GuruFocus
RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating - marketscreener.com
Barclays Updates Karyopharm (KPTI) Price Target, Eyes Future Dat - GuruFocus
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):